You just read:

Bridge Biotherapeutics Announces FDA Orphan Drug Designation for BBT-877 in Idiopathic Pulmonary Fibrosis (IPF)

News provided by

Bridge Biotherapeutics, Inc.

Jan 16, 2019, 09:00 ET